Sphere Fluidics raises £3.7m from Greenwood Way Capital and 24Haymarket to fund expansion.
Greenwood Way Capital and 24Haymarket led the financing round to support international expansion and operations.
Sphere Fluidics develops and commercialises single cell analysis systems powered by proprietary picodroplet technology. The company supports global biotherapeutic discovery and development through its automated platforms.
Sphere Fluidics has closed a funding round of £3.7m, led jointly by Greenwood Way Capital and 24Haymarket. The capital follows an earlier investment announced in January, bringing the total raised in this push to £3.7m.
The proceeds will support working capital requirements for the company flagship Cyto-Mine platform, alongside the expansion of operations in the UK and the establishment of a new sales office and laboratory in California.
From the founder
"We are delighted to raise this additional funding. Due to our over-subscribed investment round earlier this year, we decided to add on a second tranche to accommodate the additional interest. We are currently recruiting and looking at prospective new facilities in the UK and California to support the growth of our commercial and scientific activities."
Frank Craig
CEO at Sphere Fluidics
Investor perspective
"We are very pleased to have been able to assist Sphere Fluidics once again and to have introduced them to suitable investors for their various funding stages. This was our fourth funding round with them. Our members range from high net worth individuals to large family offices which have enabled us to support the Company from its early stage investment rounds to the recent larger scale-up fundraising. It has been exciting to have worked with such a professional team developing such a unique technology."
Ian Leigh
Founder, Greenwood Way Capital
Use of funds
- 01Scale operations
- 02Expand into international markets
Investors
Categories
About the company
Sphere Fluidics
Sphere Fluidics creates advanced single cell analysis systems for biotherapeutic discovery.